Tsao, Chin-HoChin-HoTsaoJhou, Rong-HongRong-HongJhouKe, Chien-ChihChien-ChihKeCHUN-WEI CHANGChang, Chi-WeiChi-WeiChangYang, Bang-HungBang-HungYangHuang, Wen-ShengWen-ShengHuangShih, Bing-FuBing-FuShihLiu, Ren-ShyanRen-ShyanLiu2023-02-102023-02-102022-09-272296-858Xhttps://scholars.lib.ntu.edu.tw/handle/123456789/627896De novo lipogenesis is upregulated in many cancers, and targeting it represents a metabolic approach to cancer treatment. However, the treatment response is unpredictable because lipogenic activity varies greatly among individual tumors, thereby necessitating the assessment of lipogenic activity before treatment. Here, we proposed an imaging probe, positron emission tomography/computed tomography (PET/CT) with dual tracers combining 11C-acetate and 18F-fluorodeoxyglucose (18F-FDG), to assess the lipogenic activity of hepatocellular carcinoma (HCC) and predict the response to lipogenesis-targeted therapy.enPET/CT; cancer metabolism; cancer therapy; de novo lipogenesis; hepatocellular carcinoma; imaging probe; lipogenesis-targeted therapyjournal article10.3389/fmed.2022.1008200362375462-s2.0-85139546755WOS:000873765600001https://api.elsevier.com/content/abstract/scopus_id/85139546755